This article has been updated

Abstract

The reversible attachment of a small-molecule drug to a carrier for targeted delivery can improve pharmacokinetics and the therapeutic index. Previous studies have reported the delivery of molecules that contain primary and secondary amines via an amide or carbamate bond; however, the ability to employ tertiary-amine-containing bioactive molecules has been elusive. Here we describe a bioreversible linkage based on a quaternary ammonium that can be used to connect a broad array of tertiary and heteroaryl amines to a carrier protein. Using a concise, protecting-group-free synthesis we demonstrate the chemoselective modification of 12 complex molecules that contain a range of reactive functional groups. We also show the utility of this connection with both protease-cleavable and reductively cleavable antibody–drug conjugates that were effective and stable in vitro and in vivo. Studies with a tertiary-amine-containing antibiotic show that the resulting antibody–antibiotic conjugate provided appropriate stability and release characteristics and led to an unexpected improvement in activity over the conjugates previously connected via a carbamate.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 03 November 2016

    In the version of this Article originally published, the structure of tubulysin was shown three times in Figure 5 and in each instance the five-membered ring was missing a nitrogen atom. This has been corrected in the online versions of this Article.

References

  1. 1.

    & Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93, 52–79 (2015).

  2. 2.

    , & Antibody–drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. 53, 3796–3827 (2014).

  3. 3.

    , , & Prodrug strategies in anticancer chemotherapy. ChemMedChem 3, 20–53 (2008).

  4. 4.

    & Prodrug chemotherapeutics bypass P-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 23, 3613–3621 (2004).

  5. 5.

    , , , & Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc. Natl Acad. Sci. USA 105, 12128–12133 (2008).

  6. 6.

    , & Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. Adv. Drug Deliv. Rev. 65, 1731–1747 (2013).

  7. 7.

    , & Anticancer carrier-linked prodrugs in clinical trials. Expert Opin. Invest. Drugs 16, 1037–1058 (2007).

  8. 8.

    , , & Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Dev. 9, 218–230 (2006).

  9. 9.

    et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus. Nature 527, 323–328 (2015).

  10. 10.

    et al. An immunosuppressive antibody–drug conjugate. J. Am. Chem. Soc. 137, 3229–3232 (2015).

  11. 11.

    & Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 8, 3341–3346 (1998).

  12. 12.

    , & A novel connector linkage applicable in prodrug design. J. Med. Chem. 24, 479–480 (1981).

  13. 13.

    et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778–784 (2003).

  14. 14.

    & Natural products as exquisitely potent cytotoxic payloads for antibody–drug conjugates. Curr. Top. Med. Chem. 14, 2822–2834 (2015).

  15. 15.

    et al. Auristatin antibody–drug conjugate physical instability and the role of drug payload. Bioconjugate Chem. 25, 656–664 (2014).

  16. 16.

    , , , & Design of therapeutic proteins with enhanced stability. Proc. Natl Acad. Sci. USA 106, 11937–11942 (2009).

  17. 17.

    et al. Synthesis and evaluation of hydrophilic linkers for antibody–maytansinoid conjugates. J. Med. Chem. 54, 3606–3623 (2011).

  18. 18.

    et al. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates. J. Med. Chem. 48, 1344–1358 (2005).

  19. 19.

    , & Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjugate Chem. 19, 1113–1118 (2008).

  20. 20.

    & Choosing an effective protein bioconjugation strategy. Nat. Chem. Biol. 7, 876–884 (2011).

  21. 21.

    & Site-specific antibody–drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjugate Chem. 26, 176–192 (2015).

  22. 22.

    & Selective chemical protein modification. Nat. Commun. 5, 4740 (2014).

  23. 23.

    & Electron-transfer processes. VIII. Coupling reactions of radicals with carbanions. J. Am. Chem. Soc. 90, 347–353 (1968).

  24. 24.

    & Electron paramagnetic resonance spectra of α-substituted nitrotoluene anion radicals. Influence of electron-withdrawing substituents on the coupling constants for β-hydrogen atoms. J. Am. Chem. Soc. 97, 5620–5622 (1975).

  25. 25.

    , & Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins showing very high in vitro selectivity. J. Med. Chem. 36, 2578–2579 (1993).

  26. 26.

    , & A survey of Hammett substituent constants and resonance and field parameters. Chem. Rev. 91, 165–195 (1991).

  27. 27.

    & Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 6, 764–775 (2006).

  28. 28.

    et al. The refined 2.15 Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J. 10, 2321–2330 (1991).

  29. 29.

    et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc. 109, 6883–6885 (1987).

  30. 30.

    et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J. Med. Chem. 57, 10527–10543 (2014).

  31. 31.

    et al. Isolation, crystal and solution structure determination, and biosynthesis of tubulysins—powerful inhibitors of tubulin polymerization from myxobacteria. Angew. Chem. Int. Ed. 43, 4888–4892 (2004).

  32. 32.

    , , & Potent vinblastine C20′ ureas displaying additionally improved activity against a vinblastine-resistant cancer cell line. ACS Med. Chem. Lett. 4, 985–988 (2013).

  33. 33.

    et al. New antitumor monoclonal antibody–vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity. J. Med. Chem. 32, 548–555 (1989).

  34. 34.

    De novo synthesis of substituted pyridines. Tetrahedron 60, 6043–6061 (2004).

  35. 35.

    & Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin. Cancer Res. 69, 171–177 (2009).

  36. 36.

    et al. Suitable labels for molecular imaging—influence of dye structure and hydrophilicity on the spectroscopic properties of IgG conjugates. Bioconjugate Chem. 22, 1298–1308 (2011).

  37. 37.

    . et al. Peptidomimetic compounds and antibody–drug conjugates thereof. World Intellectual Property Organization patent 2015/095227 A2 (2015).

  38. 38.

    , et al. Releasable luciferin-transporter conjugates: tools for the real-time analysis of cellular uptake and release. J. Am. Chem. Soc. 128, 6526–6527 (2006).

  39. 39.

    , , , & Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl Acad. Sci. USA 103, 13872–13877 (2006).

  40. 40.

    et al. An assembly concept for the consecutive introduction of unsymmetrical disulfide bonds: synthesis of a releasable multidrug conjugate of folic acid. J. Org. Chem. 72, 5968–5972 (2007).

  41. 41.

    et al. Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates. Chem. Sci. (2016).

  42. 42.

    & 149. Dithiols. part XII. The alkaline hydrolysis of acetylated hydroxy-thiols: a new reaction for the formation of cyclic sulphides. J. Chem. Soc. (1952).

  43. 43.

    Design and synthesis of releasable folate–drug conjugates using a novel heterobifunctional disulfide-containing linker. Bioorg. Med. Chem. Lett. 18, 3196–3199 (2008).

  44. 44.

    et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925–932 (2008).

Download references

Acknowledgements

We thank F. Fan, Z. Xu, J. Wai, H. Raab, B. Lin, K. Xu and A. Deese for helping in the preparation and analysis of the materials used in the study, and S. Spencer and R. Rowntree for coordinating the studies.

Author information

Affiliations

  1. Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA

    • Leanna R. Staben
    • , Stefan G. Koenig
    • , Sophie M. Lehar
    • , Richard Vandlen
    • , Donglu Zhang
    • , Josefa Chuh
    • , Shang-Fan Yu
    • , Carl Ng
    • , Jun Guo
    • , Yanzhou Liu
    • , Aimee Fourie-O'Donohue
    • , MaryAnn Go
    • , Xin Linghu
    • , Nathaniel L. Segraves
    • , BinQing Wei
    • , Gail D. Lewis Phillips
    • , Keyang Xu
    • , Katherine R. Kozak
    • , Sanjeev Mariathasan
    • , John A. Flygare
    •  & Thomas H. Pillow
  2. WuXi AppTec Co., Ltd, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China

    • Tao Wang
    •  & Jinhua Chen

Authors

  1. Search for Leanna R. Staben in:

  2. Search for Stefan G. Koenig in:

  3. Search for Sophie M. Lehar in:

  4. Search for Richard Vandlen in:

  5. Search for Donglu Zhang in:

  6. Search for Josefa Chuh in:

  7. Search for Shang-Fan Yu in:

  8. Search for Carl Ng in:

  9. Search for Jun Guo in:

  10. Search for Yanzhou Liu in:

  11. Search for Aimee Fourie-O'Donohue in:

  12. Search for MaryAnn Go in:

  13. Search for Xin Linghu in:

  14. Search for Nathaniel L. Segraves in:

  15. Search for Tao Wang in:

  16. Search for Jinhua Chen in:

  17. Search for BinQing Wei in:

  18. Search for Gail D. Lewis Phillips in:

  19. Search for Keyang Xu in:

  20. Search for Katherine R. Kozak in:

  21. Search for Sanjeev Mariathasan in:

  22. Search for John A. Flygare in:

  23. Search for Thomas H. Pillow in:

Contributions

L.R.S., S.G.K., X.L., T.W., J.C. and T.H.P. designed and/or synthesized the linker–drug conjugates. S.M.L. designed, executed and analysed data for the in vitro antibiotic experiment. R.V. characterized cathepsin cleavage of linker–drug conjugates and ADCs. D.Z. characterized GSH reduction of the disulfide linker–drug conjugate. J.C. characterized the in vitro potency of cytotoxic ADCs. S.-F.Y. designed and analysed data for in vivo efficacy. C.N. characterized and analysed data for in vivo stability. J.G. characterized the potency of the free cytotoxic drugs. Y.L. confirmed the structure of linker–drug conjugates through NMR studies. A.F.-O. characterized the conjugate stability in whole blood. M.G. performed in vivo efficacy experiments. N.L.S. purified and characterized an antibiotic linker–drug conjugate. B.W. designed a peptidomimetic linker. G.D.L.P, K.X., K.R.K, S.M., J.A.F. and T.H.P. led groups on the project responsible for chemistry, biology and in vitro or in vivo characterization. T.H.P. conceived and initiated the project. T.H.P. wrote the manuscript with help and input from all of the authors.

Competing interests

All authors are full time employees of Genentech or WuXi AppTec.

Corresponding author

Correspondence to Thomas H. Pillow.

Supplementary information

PDF files

  1. 1.

    Supplementary information

    Supplementary information

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nchem.2635

Further reading